- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02956876
Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer (INCISIVE)
Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer, Requiring Intravenous Chemotherapy Versus a Medical Monitoring
With 42,150 new cases per year, colorectal cancer is the third cause of cancer in France according to the latest report from the Institut national du Cancer (INCa). Second leading cause of cancer death in men, its management is a public health problem. According to projections by WHO, the prevalence of cancers expected to increase 50% by 2050 especially in digestive oncology. These projections can be concluded that the demand for care will continue to be growing.
Medical advances and societal leading to increased life expectancy, have operated a mutation of the cancer disease. Formerly fatal disease, it is now a chronic disease in some cases. These changes are causing new challenges for the health system.
To address this problem, it is asked health professionals to adapt the organization of health care delivery to improve efficiency, in a constrained economic environment. To this end, action 4.1 of the cancer plan includes the creation of clinical nursing profession, a proposal reiterated in article 120 of the French Health System Law. Nursing clinicians will be empowered to ensure, under certain conditions, prescription treatments protocolized of follow-up tests, further treatment and support, as well as the extension or adaptation of specific treatments.
This project is a first step, in France, in thinking around new organizations in the supply of care in oncology.
For patients, strengthening their monitoring during chemotherapy, will better know their tolerance regarding chemotherapy. This optimized management of chemotherapy-induced effects will help reduce the use of emergency care.
The establishment of such a practitioner will free medical time to handle the most complex patients and perform tasks related to research.
For hospital pharmacies this type of organization will optimize their productivity by anticipating orders for chemotherapy pockets.
This project represents an opportunity to demonstrate the added value of advanced practice nurses in France in the health system and particularly in oncology. It also adds value to clinical expertise nurse and register the profession in the research.
The hypothesis is that the quality and safety of care provided by a nurse practitioner are equivalent to those provided by a doctor at follow-up of patients with gastrointestinal cancer, treated with intravenous chemotherapy.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Hélène MAGNIER
- E-mail: helene.magnier@chu-rouen.fr
Studiesteder
-
-
-
Rouen, Frankrig
- Rekruttering
- Rouen University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Digestive diagnostic of colorectal cancer.
- Treatment with intravenous chemotherapy or treatment with concomitant oral and intravenous chemotherapy.
- Patient beginning a cycle of chemotherapy he had already received chemotherapy sessions or not.
- Patient aged 18 or over.
- Patient with predictable life expectancy greater than 3 months.
- Patient speak and understand the French.
- Patient having read and understood the information letter and signed the consent form.
- For women of childbearing age: effective contraception 3 months before the start of treatment and negative blood pregnancy test
Exclusion Criteria:
- Patient aged over 80.
- Patient aged under 18.
- Prognosis committed within 3 months.
- Pregnant women or breastfeeding.
- Initial clinical assessment quoting fatigue to a higher grade 2 according to the WHO classification before the start of chemotherapy treatment.
- Against indication(s) for chemotherapy.
- Person deprived of liberty by an administrative or judicial decision or person under the protection of a conservator.
- History of disease or psychological or sensory abnormality that may prevent the patient to understand the requirements for participation in the protocol or preventing it from giving informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Nurse practitioner consultation
standard chemotherapy for colorectal cancer
|
standard chemotherapy for colorectal cancer
Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
|
Andet: Standard consultation
standard chemotherapy for colorectal cancer
|
standard chemotherapy for colorectal cancer
Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of side effects of chemotherapy for WHO grade greater than 2
Tidsramme: Day 7
|
Day 7
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Quality of life of patients by QLQC-30 questionnaire
Tidsramme: Day 7
|
Day 7
|
Number of provisional chemotherapy orders
Tidsramme: Day 7
|
Day 7
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2015/211/HP
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ColoRektal Cancer
-
University of ArkansasAktiv, ikke rekrutterendeColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAktiv, ikke rekrutterendeMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater